Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Power Medical Interventions Inc.

This article was originally published in Start Up

Executive Summary

Power Medical Interventions Inc. hopes that nice mid-size device companies can finish first. This three-year old device company has already hit the market with the first incarnation of its computer-assisted wound closure platform: a surgical stapling system that will allow automated stapling in areas of the body that are inaccessible to current, rigid devices.

You may also be interested in...

The Other Diabetes: An Interventional Market Emerges

The American Society for Bariatric Surgery recently changed its name to the American Society for Bariatric and Metabolic Surgery, in recognition of the link between obesity and Type 2 diabetes. Published data has long shown that in many cases, when morbidly obese patients with Type 2 diabetes lose weight--through gastric bypass surgery or other means--their glucose levels return to normal. That's old news. But something new is happening: bariatric surgeons and companies with implantable devices originally intended for weight loss are publishing data that shows a reversal in Type 2 diabetes, sometimes independently of a reduction in weight, by some other mechanisms as yet unproven. In September, the "First World Congress On Interventional Therapies for Type 2 Diabetes" convened the clinical community and industry to discuss new treatment strategies.

NOTES: Revolutionizing Surgery

NOTES is an experimental alternative to conventional surgery that uses a combination of endoscopic and laparoscopic techniques to access the peritoneal cavity through the wall of the alimentary canal or other natural orifices, allowing surgeons and gastroenterologists to perform complex surgery without leaving any visible scars. In the last few years, NOTES research, procedures, patents, and venture capital investment have increased exponentially. And although the field is still unproven, the rush to NOTES is being fueled by several important motivators, including the perceived advantages over conventional surgery, patient demand, and a worldwide market potential believed to range between $2 and $4 billion per year.

NOTES Companies Sing an Upbeat Tune

There was an almost dot-com-like euphoria about NOTES at 2007's annual meetings of endoscopists and surgeons. NOTES (natural orifice translumenal endoscopic surgery) is being described as a revolution in minimally invasive surgery, incisionless surgery, or at the very least, a major advance over laparoscopy. It represents a billion-dollar category not yet dominated by the companies that gained preeminence in the $4 billion worldwide laparoscopy market. But most companies in the area agree that the NOTES revolution isn't going to happen overnight. The challenge for today is to create products and technologies for procedures that can happen in high volume in the near term, while waiting for more advanced NOTES procedures to come about.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts